Evidence map›Paper›PMID 39085818›Full record

Observational studyBMC pulmonary medicine2024

Comparison of Budesonide/formoterol versus Fluticasone furoate/vilanterol as maintenance and reliever therapy for asthma control: a real-world observational study.

Wei-Chun Huang, Wen-Chien Cheng, Chih-Yu Chen, Wei-Chih Liao, Biing-Ru Wu, Wei-Chun Chen, Chih-Yen Tu, Chia-Hung Chen, Wu-Huei Hsu

Abstract readObservational StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei-Chun HuangDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.
Wen-Chien ChengDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan. wcchengdr@gmail.com.
Chih-Yu ChenDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.
Wei-Chih LiaoDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.
Biing-Ru WuDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.
Wei-Chun ChenDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.
Chih-Yen TuDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.
Chia-Hung ChenDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan. hsnu758@gmail.com.
Wu-Huei HsuDivision of Pulmonary and Critical Care, Department of Internal Medicine, North District, China Medical University Hospital, No. 2, Yude Road, Taichung City, 40402, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies have reported reduced acute exacerbation rates and improved symptom control in asthma patients treated using inhaled corticosteroids plus formoterol maintenance and reliever therapy (MART). Fluticasone furoate (FF) and vilanterol (VIL) also provide rapid bronchodilation and sustained anti-inflammatory effects, however no studies have investigated FF/VIL as MART for asthma control.

methodsFrom October 1, 2021 to September 30, 2023, this retrospective study included asthma patients classified as step 3 or 4 according to the Global Initiative for Asthma guidelines, who were then divided into two groups. One group received BUD/FOR as MART, while the other received FF/VIL as MART. Pulmonary function tests, exacerbation rates, Asthma Control Test (ACT), fractional exhaled nitric oxide (FeNO) levels, and blood eosinophil counts were measured before and after 12 months of treatment.

resultsA total of 161 patients were included, of whom 36 received BUD/FOR twice daily as MART, and 125 received FF/VIL once daily as MART. After 12 months of treatment, the FF/VIL group showed a significant increase in ACT scores by 1.57 (p < 0.001), while the BUD/FOR group had an increase of 0.88 (p = 0.11). In terms of FeNO levels, the BUD/FOR group experienced a decline of -0.2 ppb (p = 0.98), whereas the FF/VIL group had a mild increase of + 0.8 ppb (p = 0.7). Notably, there was a significant difference in the change of FeNO between the two groups (∆ FeNO: -0.2 ppb in BUD/FOR; + 0.8 ppb in FF/VIL, p < 0.001). There were no significant alterations observed in FEV1, blood eosinophil count, or acute exacerbation decline in either group.

conclusionsIn the current study, patients treated with FF/VIL as MART showed improvements in ACT scores, while those treated with BUD/FOR as MART exhibited a reduction in FeNO levels. However, the difference between the two treatment groups did not reach clinical significance. Thus, FF/VIL as MART showed similar effectiveness to BUD/FOR as MART.

Indexed as

AsthmaBenzyl AlcoholsChlorobenzenesDrug CombinationsAdministration, InhalationAdultAgedAndrostadienesAnti-Asthmatic AgentsBronchodilator AgentsBudesonideBudesonide, Formoterol Fumarate Drug CombinationEosinophilsFemaleFormoterol FumarateHumansAndrostadienesAnti-Asthmatic AgentsBenzyl AlcoholsBronchodilator AgentsBudesonideBudesonide, Formoterol Fumarate Drug CombinationChlorobenzenesDrug Combinationsfluticasone furoatefluticasone furoate-vilanterol trifenatateFormoterol FumarateNitric Oxidevilanterol

Identifiers

PMID39085818
PMCPMC11293254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.